Desvenlafaxine is used for the treatment of major depressive disorder. It belongs to the class of substances termed SNRIs ‘ selective serotonin and norepinephrine reuptake inhibitors.
These substances augment the signaling of serotonin and norepinephrine in the central nervous system, causing elevated mood. Desvenlafaxine is administered orally in extended-release tablet. It is the major active metabolite of the antidepressant venlafaxine. Currently it is being studied for effectiveness in generalized anxiety disorder (GAD).
In 2013, desvenlafaxine was approved by the FDA under the trade name Khedezla. Previously, in 2008, it was approved by the FDA in the form of desvenlafaxine succinate, under the trade name Pristiq. It is produced through a chemical process involving several steps.